BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target.

Bezrookove, Vladimir; Khan, Imran A; Nosrati, Mehdi; Miller, James R; McAllister, Sean; Dar, Altaf A; Kashani-Sabet, Mohammed

Bezrookove, Vladimir; Khan, Imran A; Nosrati, Mehdi; Miller, James R; McAllister, Sean; Dar, Altaf A; Kashani-Sabet, Mohammed.

Afiliação

Bezrookove V; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
Khan IA; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
Nosrati M; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
Miller JR; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
McAllister S; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
Dar AA; California Pacific Medical Center Research Institute, San Francisco, CA, United States.
Kashani-Sabet M; California Pacific Medical Center Research Institute, San Francisco, CA, United States.

Front Oncol ; 12: 1011173, 2022.

Article em En | MEDLINE | ID: mdl-36530982

Palavras-chave

BPTF; ER-positive; breast cancer; oncogene; triple-negative

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google